探索性结肠炎和牛皮之间的共同机制,并通过生物信息学和分子对接来预测治疗性天然化合物
Yixuan Yang1, Zhuozhi Gong2, Jiao Yang1
1Department of Dermatology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China.
Heliyon
|September 23, 2024
概括
这项研究确定了牛皮 (PS) 和性结肠炎 (UC) 的共享生物机制和治疗点. 像奎尔丁这样的天然化合物显示出治疗这两种炎症状况的前景.
科学领域:
- 免疫学 免疫学 免疫学
- 基因组学就是基因组学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 牛皮 (PS) 和性结肠炎 (UC) 分享潜在的相关性,但对它们的共同机制的理解有限.
- 目前PS和UC的治疗方法通常涉及免疫抑制药物,具有潜在的副作用和耐药性.
- 传统中国医学为治疗PS和UC提供了一个有前途的替代方案,副作用较少.
研究的目的:
- 阐明UC和PS背后的共享生物机制.
- 为两种疾病确定共同的治疗点.
- 预测有效治疗UC和PS的自然化合物.
主要方法:
- 从基因表达综合数据库中收集并验证了UC和PS的差异表达基因.
- 使用STRING构建了一个蛋白质-蛋白质相互作用网络,以确定核心目标.
- 利用GO,KEGG,CIBERSORT,Coremine和TCMSP数据库进行功能分析,免疫细胞相关性和通过分子对接进行自然化合物预测.
主要成果:
- 在UC和PS中确定了20个共同的核心目标,其中MMP9,MMP1,CD274,CXCL10和TOP2A是最相关的.
- 在UC和PS中观察到巨细胞和树突细胞的升高,CXCL10与巨细胞密切相关.
- 常见的信号通路包括IL-17,TNF和化学激素信号. quercetin 和 baicalen 等天然化合物显示出治疗潜力.
结论:
- MMP9,MMP1和CXCL10是UC和PS共享炎症途径的关键调解者,代表着有前途的治疗点.
- 包括奎尔塞丁,卢托林和伊利索利在内的天然化合物可以作为这两种情况的有效治疗方法.
- 研究结果支持通过探索共享机制和天然化合物疗效来推进UC和PS的治疗策略.
更多相关视频
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
12.2K
09:01Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
10.0K
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
129
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
129
01:29Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
323
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
323
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
151
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
151
01:17Chronic Bowel Disorders: Introduction
408
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
408